APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preclinical Assets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Preclinical Assets Market Outlook and Growth Opportunities 2026

16 January 2026198 pages

Choose your research edition.

Industry ResearchPreclinical Assets Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Preclinical Assets Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Preclinical Assets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preclinical Assets Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Preclinical Assets Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Preclinical Assets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Preclinical Assets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Preclinical Assets market include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Preclinical Assets market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Preclinical Assets and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Preclinical Assets revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Preclinical Assets market.

Preclinical Assets Segment by Company

Eurofins Scientific

Viroclinics Xplore

SGS

Intertek Group

AmplifyBio

IQVIA

ICON plc

Medpace

Pharmatest Services

PPD

Crown Bioscience

Comparative Biosciences

TCG Lifesciences

Domainex

Absorption Systems

Preclinical Assets Segment by Type

Bioanalysis and DMPK Studies

Toxicology Testing

Compound Management

Safety Pharmacology

Others

Preclinical Assets Segment by Application

Biopharmaceutical Companies

Government Institutes

Research institutes

Others

Preclinical Assets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Preclinical Assets status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Preclinical Assets key companies, revenue, market share, and recent developments.

3. To split the Preclinical Assets breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Preclinical Assets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Preclinical Assets significant trends, drivers, influence factors in global and regions.

6. To analyze Preclinical Assets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Assets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preclinical Assets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Assets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preclinical Assets industry.

Chapter 3: Detailed analysis of Preclinical Assets company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Preclinical Assets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Preclinical Assets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Preclinical Assets Industry Trends Table 2. Preclinical Assets Industry Drivers Table 3. Preclinical Assets Industry Opportunities and Challenges Table 4. Preclinical Assets Industry Restraints Table 5. Global Preclinical Assets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Preclinical Assets Revenue Share by Company (2021-2026) Table 7. Global Preclinical Assets Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Preclinical Assets Key Company Manufacturing Base & Headquarters Table 9. Global Preclinical Assets Company, Product Type & Application Table 10. Global Preclinical Assets Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Preclinical Assets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bioanalysis and DMPK Studies Table 15. Significant Companies of Toxicology Testing Table 16. Significant Companies of Compound Management Table 17. Significant Companies of Safety Pharmacology Table 18. Significant Companies of Others Table 19. Global Preclinical Assets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Preclinical Assets Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Preclinical Assets Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Preclinical Assets Sales Value Share by Type (2021-2026) Table 23. Global Preclinical Assets Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Biopharmaceutical Companies Table 25. Significant Companies of Government Institutes Table 26. Significant Companies of Research institutes Table 27. Significant Companies of Others Table 28. Global Preclinical Assets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Preclinical Assets Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Preclinical Assets Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Preclinical Assets Sales Value Share by Application (2021-2026) Table 32. Global Preclinical Assets Sales Value Share by Application (2027-2032) Table 33. Global Preclinical Assets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Preclinical Assets Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Preclinical Assets Sales Value Share by Region (2021-2026) Table 36. Global Preclinical Assets Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Preclinical Assets Sales Value Share by Region (2027-2032) Table 38. Global Preclinical Assets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Preclinical Assets Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Preclinical Assets Sales Value Market Share by Country (2021-2026) Table 41. Global Preclinical Assets Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Preclinical Assets Sales Value Market Share by Country (2027-2032) Table 43. Eurofins Scientific Company Information Table 44. Eurofins Scientific Business Overview Table 45. Eurofins Scientific Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Eurofins Scientific Preclinical Assets Product Portfolio Table 47. Eurofins Scientific Recent Development Table 48. Viroclinics Xplore Company Information Table 49. Viroclinics Xplore Business Overview Table 50. Viroclinics Xplore Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Viroclinics Xplore Preclinical Assets Product Portfolio Table 52. Viroclinics Xplore Recent Development Table 53. SGS Company Information Table 54. SGS Business Overview Table 55. SGS Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. SGS Preclinical Assets Product Portfolio Table 57. SGS Recent Development Table 58. Intertek Group Company Information Table 59. Intertek Group Business Overview Table 60. Intertek Group Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Intertek Group Preclinical Assets Product Portfolio Table 62. Intertek Group Recent Development Table 63. AmplifyBio Company Information Table 64. AmplifyBio Business Overview Table 65. AmplifyBio Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AmplifyBio Preclinical Assets Product Portfolio Table 67. AmplifyBio Recent Development Table 68. IQVIA Company Information Table 69. IQVIA Business Overview Table 70. IQVIA Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. IQVIA Preclinical Assets Product Portfolio Table 72. IQVIA Recent Development Table 73. ICON plc Company Information Table 74. ICON plc Business Overview Table 75. ICON plc Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. ICON plc Preclinical Assets Product Portfolio Table 77. ICON plc Recent Development Table 78. Medpace Company Information Table 79. Medpace Business Overview Table 80. Medpace Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Medpace Preclinical Assets Product Portfolio Table 82. Medpace Recent Development Table 83. Pharmatest Services Company Information Table 84. Pharmatest Services Business Overview Table 85. Pharmatest Services Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pharmatest Services Preclinical Assets Product Portfolio Table 87. Pharmatest Services Recent Development Table 88. PPD Company Information Table 89. PPD Business Overview Table 90. PPD Preclinical Assets Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. PPD Preclinical Assets Product Portfolio Table 92. PPD Recent Development Table 93. Crown Bioscience Company Information Table 94. Crown Bioscience Business Overview Table 95. Crown Bioscience Preclinical Assets Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Crown Bioscience Preclinical Assets Product Portfolio Table 97. Crown Bioscience Recent Development Table 98. Comparative Biosciences Company Information Table 99. Comparative Biosciences Business Overview Table 100. Comparative Biosciences Preclinical Assets Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Comparative Biosciences Preclinical Assets Product Portfolio Table 102. Comparative Biosciences Recent Development Table 103. TCG Lifesciences Company Information Table 104. TCG Lifesciences Business Overview Table 105. TCG Lifesciences Preclinical Assets Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. TCG Lifesciences Preclinical Assets Product Portfolio Table 107. TCG Lifesciences Recent Development Table 108. Domainex Company Information Table 109. Domainex Business Overview Table 110. Domainex Preclinical Assets Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Domainex Preclinical Assets Product Portfolio Table 112. Domainex Recent Development Table 113. Absorption Systems Company Information Table 114. Absorption Systems Business Overview Table 115. Absorption Systems Preclinical Assets Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Absorption Systems Preclinical Assets Product Portfolio Table 117. Absorption Systems Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Preclinical Assets Product Image Figure 2. Global Preclinical Assets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 4. Global Preclinical Assets Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bioanalysis and DMPK Studies Image Figure 8. Toxicology Testing Image Figure 9. Compound Management Image Figure 10. Safety Pharmacology Image Figure 11. Others Image Figure 12. Global Preclinical Assets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Preclinical Assets Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Preclinical Assets Sales Value Share by Type (2021-2032) Figure 15. Biopharmaceutical Companies Image Figure 16. Government Institutes Image Figure 17. Research institutes Image Figure 18. Others Image Figure 19. Global Preclinical Assets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Preclinical Assets Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Preclinical Assets Sales Value Share by Application (2021-2032) Figure 22. Global Preclinical Assets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Preclinical Assets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Preclinical Assets Sales Value (2021-2032) & (US$ Million) Figure 25. North America Preclinical Assets Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Preclinical Assets Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Preclinical Assets Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Preclinical Assets Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Preclinical Assets Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Preclinical Assets Sales Value (2021-2032) & (US$ Million) Figure 31. South America Preclinical Assets Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Preclinical Assets Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Preclinical Assets Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Preclinical Assets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Preclinical Assets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Preclinical Assets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Safety Pharmacology
  • Others
Applications
  • Biopharmaceutical Companies
  • Government Institutes
  • Research institutes
  • Others
Companies covered
  • Eurofins Scientific
  • Viroclinics Xplore
  • SGS
  • Intertek Group
  • AmplifyBio
  • IQVIA
  • ICON plc
  • Medpace
  • Pharmatest Services
  • PPD
  • Crown Bioscience
  • Comparative Biosciences
  • TCG Lifesciences
  • Domainex
  • Absorption Systems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Preclinical Assets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Preclinical Assets Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Preclinical Assets Market Dynamics
  1. 2.1 Preclinical Assets Industry Trends
  2. 2.2 Preclinical Assets Industry Drivers
  3. 2.3 Preclinical Assets Industry Opportunities and Challenges
  4. 2.4 Preclinical Assets Industry Restraints
3 Preclinical Assets Market by Company
  1. 3.1 Global Preclinical Assets Company Revenue Ranking in 2025
  2. 3.2 Global Preclinical Assets Revenue by Company (2021-2026)
  3. 3.3 Global Preclinical Assets Company Ranking (2024-2026)
  4. 3.4 Global Preclinical Assets Company Manufacturing Base and Headquarters
  5. 3.5 Global Preclinical Assets Company Product Type and Application
  6. 3.6 Global Preclinical Assets Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Preclinical Assets Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Preclinical Assets Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Preclinical Assets Market by Type
  1. 4.1 Preclinical Assets Type Introduction
  2. 4.1.1 Bioanalysis and DMPK Studies
  3. 4.1.2 Toxicology Testing
  4. 4.1.3 Compound Management
  5. 4.1.4 Safety Pharmacology
  6. 4.1.5 Others
  7. 4.2 Global Preclinical Assets Sales Value by Type
  8. 4.2.1 Global Preclinical Assets Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Preclinical Assets Sales Value by Type (2021-2032)
  10. 4.2.3 Global Preclinical Assets Sales Value Share by Type (2021-2032)
5 Preclinical Assets Market by Application
  1. 5.1 Preclinical Assets Application Introduction
  2. 5.1.1 Biopharmaceutical Companies
  3. 5.1.2 Government Institutes
  4. 5.1.3 Research institutes
  5. 5.1.4 Others
  6. 5.2 Global Preclinical Assets Sales Value by Application
  7. 5.2.1 Global Preclinical Assets Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Preclinical Assets Sales Value by Application (2021-2032)
  9. 5.2.3 Global Preclinical Assets Sales Value Share by Application (2021-2032)
6 Preclinical Assets Regional Value Analysis
  1. 6.1 Global Preclinical Assets Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Preclinical Assets Sales Value by Region (2021-2032)
  3. 6.2.1 Global Preclinical Assets Sales Value by Region: 2021-2026
  4. 6.2.2 Global Preclinical Assets Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Preclinical Assets Sales Value (2021-2032)
  7. 6.3.2 North America Preclinical Assets Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Preclinical Assets Sales Value (2021-2032)
  10. 6.4.2 Europe Preclinical Assets Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Preclinical Assets Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Preclinical Assets Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Preclinical Assets Sales Value (2021-2032)
  16. 6.6.2 South America Preclinical Assets Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Preclinical Assets Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Preclinical Assets Sales Value Share by Country, 2025 VS 2032
7 Preclinical Assets Country-level Value Analysis
  1. 7.1 Global Preclinical Assets Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Preclinical Assets Sales Value by Country (2021-2032)
  3. 7.2.1 Global Preclinical Assets Sales Value by Country (2021-2026)
  4. 7.2.2 Global Preclinical Assets Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Preclinical Assets Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Preclinical Assets Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Preclinical Assets Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Preclinical Assets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Preclinical Assets Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Preclinical Assets Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Preclinical Assets Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Preclinical Assets Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Preclinical Assets Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Preclinical Assets Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Preclinical Assets Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Preclinical Assets Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Preclinical Assets Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Preclinical Assets Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Preclinical Assets Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Preclinical Assets Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Preclinical Assets Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Preclinical Assets Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Preclinical Assets Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Preclinical Assets Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Preclinical Assets Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Preclinical Assets Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Preclinical Assets Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Preclinical Assets Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Preclinical Assets Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Preclinical Assets Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Preclinical Assets Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Preclinical Assets Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Preclinical Assets Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Preclinical Assets Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Preclinical Assets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eurofins Scientific
  2. 8.1.1 Eurofins Scientific Company Information
  3. 8.1.2 Eurofins Scientific Business Overview
  4. 8.1.3 Eurofins Scientific Preclinical Assets Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eurofins Scientific Preclinical Assets Product Portfolio
  6. 8.1.5 Eurofins Scientific Recent Developments
  7. 8.2 Viroclinics Xplore
  8. 8.2.1 Viroclinics Xplore Company Information
  9. 8.2.2 Viroclinics Xplore Business Overview
  10. 8.2.3 Viroclinics Xplore Preclinical Assets Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Viroclinics Xplore Preclinical Assets Product Portfolio
  12. 8.2.5 Viroclinics Xplore Recent Developments
  13. 8.3 SGS
  14. 8.3.1 SGS Company Information
  15. 8.3.2 SGS Business Overview
  16. 8.3.3 SGS Preclinical Assets Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SGS Preclinical Assets Product Portfolio
  18. 8.3.5 SGS Recent Developments
  19. 8.4 Intertek Group
  20. 8.4.1 Intertek Group Company Information
  21. 8.4.2 Intertek Group Business Overview
  22. 8.4.3 Intertek Group Preclinical Assets Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Intertek Group Preclinical Assets Product Portfolio
  24. 8.4.5 Intertek Group Recent Developments
  25. 8.5 AmplifyBio
  26. 8.5.1 AmplifyBio Company Information
  27. 8.5.2 AmplifyBio Business Overview
  28. 8.5.3 AmplifyBio Preclinical Assets Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AmplifyBio Preclinical Assets Product Portfolio
  30. 8.5.5 AmplifyBio Recent Developments
  31. 8.6 IQVIA
  32. 8.6.1 IQVIA Company Information
  33. 8.6.2 IQVIA Business Overview
  34. 8.6.3 IQVIA Preclinical Assets Revenue and Gross Margin (2021-2026)
  35. 8.6.4 IQVIA Preclinical Assets Product Portfolio
  36. 8.6.5 IQVIA Recent Developments
  37. 8.7 ICON plc
  38. 8.7.1 ICON plc Company Information
  39. 8.7.2 ICON plc Business Overview
  40. 8.7.3 ICON plc Preclinical Assets Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ICON plc Preclinical Assets Product Portfolio
  42. 8.7.5 ICON plc Recent Developments
  43. 8.8 Medpace
  44. 8.8.1 Medpace Company Information
  45. 8.8.2 Medpace Business Overview
  46. 8.8.3 Medpace Preclinical Assets Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Medpace Preclinical Assets Product Portfolio
  48. 8.8.5 Medpace Recent Developments
  49. 8.9 Pharmatest Services
  50. 8.9.1 Pharmatest Services Company Information
  51. 8.9.2 Pharmatest Services Business Overview
  52. 8.9.3 Pharmatest Services Preclinical Assets Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pharmatest Services Preclinical Assets Product Portfolio
  54. 8.9.5 Pharmatest Services Recent Developments
  55. 8.10 PPD
  56. 8.10.1 PPD Company Information
  57. 8.10.2 PPD Business Overview
  58. 8.10.3 PPD Preclinical Assets Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PPD Preclinical Assets Product Portfolio
  60. 8.10.5 PPD Recent Developments
  61. 8.11 Crown Bioscience
  62. 8.11.1 Crown Bioscience Company Information
  63. 8.11.2 Crown Bioscience Business Overview
  64. 8.11.3 Crown Bioscience Preclinical Assets Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Crown Bioscience Preclinical Assets Product Portfolio
  66. 8.11.5 Crown Bioscience Recent Developments
  67. 8.12 Comparative Biosciences
  68. 8.12.1 Comparative Biosciences Company Information
  69. 8.12.2 Comparative Biosciences Business Overview
  70. 8.12.3 Comparative Biosciences Preclinical Assets Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Comparative Biosciences Preclinical Assets Product Portfolio
  72. 8.12.5 Comparative Biosciences Recent Developments
  73. 8.13 TCG Lifesciences
  74. 8.13.1 TCG Lifesciences Company Information
  75. 8.13.2 TCG Lifesciences Business Overview
  76. 8.13.3 TCG Lifesciences Preclinical Assets Revenue and Gross Margin (2021-2026)
  77. 8.13.4 TCG Lifesciences Preclinical Assets Product Portfolio
  78. 8.13.5 TCG Lifesciences Recent Developments
  79. 8.14 Domainex
  80. 8.14.1 Domainex Company Information
  81. 8.14.2 Domainex Business Overview
  82. 8.14.3 Domainex Preclinical Assets Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Domainex Preclinical Assets Product Portfolio
  84. 8.14.5 Domainex Recent Developments
  85. 8.15 Absorption Systems
  86. 8.15.1 Absorption Systems Company Information
  87. 8.15.2 Absorption Systems Business Overview
  88. 8.15.3 Absorption Systems Preclinical Assets Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Absorption Systems Preclinical Assets Product Portfolio
  90. 8.15.5 Absorption Systems Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst